ZURICH, March 21 (Reuters) - Lonza Group (LONN.S) said on Monday it signed a manufacturing agreement with Sweden's Oasmia Pharmaceutical (OASM.ST) for ovarian cancer drug candidate Cantrixil that was licensed by Oasmia from the Australian pharmaceutical company Kazia last year.
SYDNEY, March 2, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB (STO: OASM), an innovation-focused specialty pharmaceutical company, for Cantrixil (TRX-E-002-1), a clinical-stage, first-in-class drug candidate under development for the treatment of ovarian cancer.
Oasmia Pharmaceutical, an innovation-focused specialty pharmaceutical company, is set to acquire exclusive global development rights for Kazia Therapeutics’ ovarian cancer drug candidate Cantrixil in a $44 million deal.